MedPath

Single Site, Single Subject, Treatment IND With Mannkind Corporation's Technosphere Inhalation System

Not Applicable
Withdrawn
Conditions
Diabetes
Interventions
Drug: Technosphere® Insulin Inhalation System
Registration Number
NCT01459133
Lead Sponsor
South Orange County Endocrinology
Brief Summary

The purpose of this program is to allow patients with diabetes and with specific medical needs which require them to use this investigational inhaled insulin product in order to adequately manage their diabetes. Treatment use of this investigational product is only anticipated when exceptional need is identified by a treating physician on a per patient case by case review.

Detailed Description

This program is for patients who have been diagnosed with diabetes mellitus and has established a need for treatment with this investigational product documented by a health care professional. The treating doctor, or a member of his/her staff, will discuss the specific requirements for participation with the subject.

INVESTIGATIONAL PRODUCT DESCRIPTION:

Technosphere® Insulin Inhalation System includes Technosphere® Insulin Inhalation Powder and inhaler. The Inhalation Powder comes in 10 unit and 20 unit cartridges.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Documented diagnosis with diabetes mellitus and have established a need for treatment with the investigational product.

Local Ethics Committee approval has been documented, as needed. Patient has signed the Informed Consent Form for participation. Patient has successfully completed training on the Technosphere Insulin Inhalation System.

Exclusion Criteria

Allergy to Insulin. Smoking in the previous 6-months. History of asthma or COPD or any other significant pulmonary disease, or exposure to pulmonary toxins.

Clinical significant abnormality in screening laboratory tests. Positive pregnancy test or the intention to become pregnant. Women of childbearing age without appropriate method of contraception.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Technosphere® Insulin Inhalation SystemTechnosphere® Insulin Inhalation SystemSingle Site, Single Subject use of Technosphere® Insulin Inhalation System
Primary Outcome Measures
NameTimeMethod
Efficacy of Inhaled Insulin versus Subcutaneous Insulin in a patient who receives inadequate response from subcutaneous alone.12-months

Evaluate fasting plasma glucose and hemoglobin a1c

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

South Orange County Endocrinology

🇺🇸

Laguna Hills, California, United States

© Copyright 2025. All Rights Reserved by MedPath